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Abstract: Combretum padoides Engl. & Diels, C. psidioides Welv. and C. zeyheri Sond. are used for
the treatment of infections and tuberculosis related symptoms in African traditional medicine. In order
to verify these uses, extracts were screened for their growth inhibitory effects against M. smegmatis
ATCC 14468. Ultra-high pressure liquid chromatography coupled to quadrupole time-of-flight
mass spectrometry (UHPLC/QTOF-MS) and GC-MS were used to investigate the polyphenolic
composition in the active extracts. The lowest minimum inhibitory concentration (MIC), 625 µg/mL,
was shown by a methanol extract of the stem bark of C. psidioides. A butanol extract of C. psidioides
gave large inhibition zone diameters (IZD 21 mm) and inhibited 84% of the mycobacterial growth
at 312 µg/mL. Combretastatin B-2 and dihydrostilbene derivatives were present in the methanol
extract of C. psidioides, whereas the butanol extract of this species contained punicalagin, corilagin,
and sanguiin H-4. Methanol and butanol extracts of the stem bark of C. padoides gave large inhibition
zone diameters (IZD 26.5 mm) and MIC values of 1250 and 2500 µg/mL, respectively. C. padoides
contained an ellagitannin with a mass identical to punicalagin ([M-H]− 1083.0587) and a corilagin
like derivative ([M-H]− 633.0750) as well as ellagic acid arabinoside and methyl ellagic acid xyloside.
A butanol extract of the roots of C. zeyheri showed mild antimycobacterial activity and contained
a gallotannin at m/z [M-H]− 647.0894 as the main compound along with punicalagin and three
unknown ellagitannins at m/z [M-H]− 763.0788, 765.0566, and 817.4212. Our results indicate that
the studied species of Combretum contain phenolic and polyphenolic compounds with possible
potential as leads for antimycobacterial drugs or as adjuvants for conventional anti-TB drugs.
Keywords: Combretum spp.; antimycobacterial; hydrolysable tannins; stilbenes; African traditional medicine
1. Introduction
Tuberculosis (TB) continues to be of global concern [1]. Worldwide, TB is among the top ten
causes of death, and according to World Health Organization [1], 1.2 million people died from TB in
2018. Developing countries have significantly higher incidents of TB due to malnutrition, poverty,
and crowded settings [2]. In the African region, the incidence rate of TB is estimated to be 363 per
100,000 compared to 4.4 per 100,000 in the United States [3,4]. Moreover, up to 22.4% of the population
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in Africa is infected with latent TB [5]. In Sub-Saharan Africa, the HIV/AIDS epidemic has contributed
to create a large reservoir of TB susceptible individuals [6–9].
Drug-resistant TB continues to be a global health threat and multidrug-resistant (MDR-TB)
and extensively drug-resistant (XDR-TB) strains of M. tuberculosis are common in Africa [1,10].
Interruption of TB medication due to long treatment courses of 6–9 months has been thought to be
the primary contributor to the emergence of drug resistant TB [2,11,12]. The multidrug-resistant strains
of M. tuberculosis, which are resistant to the two first-line TB drugs, rifampicin and isoniazid, are
estimated to result in up to 91% mortality among AIDS patients [13,14]. MDR-TB therapy is more
costly, prolonged, and toxic than conventional TB therapy since several drugs, often eight to nine,
are used in combination and, in addition, the cure rates are uncertain [15]. The need for finding new
and more efficient low-toxic anti-tuberculosis scaffolds is therefore urgent [15,16].
Efforts to identify new anti-TB drugs have been made by screening pharmaceutical library
collections, but the efficiency has been poor due to limited chemical diversity in these collections [17].
There is a re-emergence in the interest of natural products as providers of novel structures for
antibacterial leads [18]. Natural products, and among them plant derived products, are rich in chemical
diversity and thus new anti-TB compounds might be found from plants, and especially from plants
used in traditional medicinal systems for TB related symptoms, such as chronic cough, bloody cough,
and chest pain [19,20]. Plant derived compounds might act on other sites with other mechanisms of
actions than the conventional antibiotics [21]. A number of antimycobacterial compounds have been
explored from plants, among them (+)-calanolide A and abruquinone B with MIC 3.13 and 12.5 µg/mL,
respectively, against M. tuberculosis [18,22,23].
Tropical rain forests, savanna and Miombo woodland forests and other forest biomes in Africa
have a high biodiversity, which increases the possibilities for finding new scaffolds for antimicrobial
drugs [24,25]. Moreover, there is still a large number of plant species, endemic to Africa, which have not
been investigated for their antimicrobial potential [21]. The genus Combretum (Combretaceae) comprises
about 250–370 species of trees, shrubs, and woody climbers in tropical and subtropical regions of
Africa, the Arabic peninsula, Madagascar, India, Asia, Australia, and America [26,27]. The genus has
its greatest species diversity in Africa with roughly 300 species [28], and an estimated 163 species occur
in tropical Sub-Saharan Africa [29,30]. Combretum species occur in a variety of habitats, including
Miombo woodlands, dry woodlands, riverine forests, and savannas [31]. Species of Combretum have
characteristic 4–5 winged fruits, which are important for species characterization [31]. Many species
resemble each other closely to their morphology and are therefore usually perceived as a common
“Combretum-group” with the vernacular name “Mlama”, by traditional healers in Tanzania, although
separate vernacular names are sometimes used to distinguish between species [32]. At least twenty-four
species of Combretum have documented uses in African traditional medicine [33]. Species of Combretum
are commonly used as decoctions, infusions, and macerations for the treatment of infectious diseases
and their symptoms such as diarrhea, cough, fever, chest-pain, and vomiting [33–41]. Some species of
Combretum are reported to be used specifically for tuberculosis, such as C. hereroense, C. molle and C.
collinum [2,33,41,42]. The frequent use of Combretum spp. in traditional medicine for the treatment of
infectious diseases indicates that they contain valuable (novel) antimicrobial compounds.
De Morais Lima et al. [43] give a comprehensive review on antimicrobial and other biological
activities of African and Asian Combretum spp. According to this review, there is a wealth of studies
concerning the growth inhibitory activities of various species of Combretum against a number of
gram-positive and gram-negative bacteria. However, fewer investigations have been performed
involving mycobacteria. Most of these investigations were performed using extracts and most of them
involved other mycobacterial species than Mycobacterium tuberculosis.
Several compound classes and among them unusual compounds [44] have been characterized from
species of Combretum, such as tetra- and pentacyclic triterpenes and their desmosides [45–54], cyclobutane
chalcone dimers [55], cycloartane triterpenes [56], diarylpropanes [57,58], flavonoids [59,60], substituted
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bibenzyls and 9,10-dihydrophenanthrenes [61–68], alkaloids and flavonoid alkaloids [69,70], ellagic acid
derivatives [71–73], ellagitannins [13,60,74–76], and gallotannins [60].
Some recent references on phytochemicals from Combretum spp. indicate that the genus contains
compounds with topoisomerase activity, such as myricitrin, a flavonoid rhamnoside that was isolated
from Combretum lanceolatum, a Brazilian medicinal plant [77]. Topoisomerase I is essential for the viability
of M. tuberculosis and is therefore considered an important drug target for antimycobacterial compounds.
To date, the most active antimycobacterial compound in the genus Combretum, the diarylpropane,
1-(2-hydroxy-4-methoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)propane, was isolated from the Asian
species Combretum griffithii and inhibited the growth of M. tuberculosis with a MIC value of
3.13 µg/mL [57,58]. Moreover, the ellagitannin punicalagin, isolated from an acetone extract of the stem
bark of Combretum molle gave mild growth inhibitory effects against strains of M. tuberculosis [13].
Cholest-5-en-3-ol, 2-phyten-1-ol, gallocatechin, and apigenin isolated from Combretum paniculatum
were active against Mycobacterium vaccae [73].
The aim of the present study was to investigate the antimycobacterial effects of the crude
methanolic extracts of Combretum psidioides, C. fragrans, and C. zeyheri and their liquid partition fractions
on the fast-growing model bacterium for tuberculosis, Mycobacterium smegmatis. The species of
Combretum were selected based on their frequent uses in African traditional medicine to treat bacterial
infections and symptoms related to them, such as cough (Table 1), as well as due to the scarcity or absence
of antimycobacterial studies on these particular African species of Combretum. Moreover, the Combretum
species chosen have given promising antibacterial and antifungal effects in our previous studies [78,79].
HPLC-DAD fingerprinting of the active extracts was performed, with special emphasis on polyphenols.
Ellagitannins were found to occur in a high variety in the studied plants and this compound class was
therefore studied in depth. There are a limited number of studies on ellagitannins in Combretum species,
despite their predominance in decoctions, macerations, and other common traditional medicinal
preparations of these plants. Therefore, ellagitannins (and especially their metabolites, the urolithins)
are suggested to be important active ingredients in these preparations. We have used HPLC-DAD
and UHPLC/QTOF-MS to elucidate UV absorption maxima, retention times and the molecular masses
of ellagitannins and other phenolic compounds. In addition, some dihydrostilbenoid compounds of C.
psidioides stem bark were characterized using GC-MS.
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Table 1. Summary of applications in traditional medicine and antimicrobial activity as well as identified compounds of the species of Combretum used in this study.
Combretum Species Uses of Plant Species in TM Way of Preparation in Traditional Medicine Antibacterial and Antimycobacterial Effects Identified Compounds
C. padoides Engl. & Diels, Thicket bush-willow
(P. Fyhrquist & L. Mwasumbi Voucher 1697070)
Leaves and roots:
For treatment of snakebites, wounds, hookworms,
bloody diarrhea, malaria and conjunctivitis [30,37,41].
Water extracts of leaves for snakebites and root
decoctions for hookworms. Crushed leaves for
wounds [30,37,41].
Extracts of the leaves gave excellent inhibitory effects
against E. coli and E. aerogenes at 0.8 mg/mL [80]; Stem
bark extracts gave good antibacterial and antifungal
effects [78,79].
1α,23β-dihydroxy-12-oleanen-29-oic-acid-
23β-O-α-4-acetylrhamnopyranoside
and 1,22-dihydroxy-12-oleanen-30-oic acid from leaves
gave antibacterial effects against S. aureus and E. coli [50].
Crude MeOH extract of stem bark and its BuOH fraction
inhibit Mycobacterium smegmatis (AI is 50.5% of
the inhibitory effect of rifampicin, MIC 1250–2500 µg/mL,
IZD 26.5 mm). *
Leaves contain rhamnose based mono- and bi-desmosidic
triterpenoids [46,47], leaves contain oleanane-type
triterpenoid glycoside,
1α,23β-dihydroxy-12-oleanen-29-oic-acid-23β-O-
α-4-acetylrhamnopyranoside and two known triterpenoids;
1,22-dihydroxy-12-oleanen-30-oic acid
and 24-ethylcholesta-7,22,25-trien-O-β-d-glucopyranoside [50].
Punicalagin and a corilagin derivative and twenty-four
other unknown ellagitannins, five gallotannins and five
ellagic acid derivatives; ellagic acid arabinoside and methyl
ellagic acid xyloside in an antimycobacterial BuOH extract
of stem bark. *
C. psidioides Welw.
Velvet bush-willow
C. psidioides, continued
(P. Fyhrquist & L. Mwasumbi Voucher 1697037)
Leaves and roots:
Aphrodisiac, diarrhea, malaria, back pain,
galactogogue [34].
Leaves and roots used for diarrhea, muscle pain,
oedema [78].
Decoctions of roots, leaf extracts or leaves mixed with
maize porridge (Ugali) for treatment of diarrhea
and oedema [78].
Broad-spectrum antibacterial profile in our earlier
investigation [78] as well as some antifungal effects [79].
Crude methanol extract and its butanol and CHCl3
fractions were growth inhibitory against Mycobacterium
smegmatis (MIC 625-2500 µg/mL). *
Substituted phenanthrenes and bibenzyls from heartwood
and stem bark [63]; Oleanane and ursane pentacyclic
triterpene glucosides from root bark [48].
Combretastatin B-2 was tentatively identified in a methanol
extract of the stem bark. Sixteen ellagitannins including
corilagin and its isomer and punicalagin, six gallotannins
including 1,6-di-O-galloyl-β-d-glucose, epigallocatechin
gallate, four ellagic acid derivatives and protocatechuic acid
were identified in a butanol extract of the stem bark. *
C. zeyheri Sond., Large-fruited bush-willow
(P. Fyhrquist & L. Mwasumbi Voucher 1697020)
Leaves, roots and stem bark:
Wounds, cough (TB?), malaria, diarrhea,
inflammation, scorpion sting, back pain, dysentery,
hook worms, tooth ache, eye lotion [35,37,38].
Diarrhea, cancer (stomach tumors) [78].
Smoke of burnt leaves inhaled for cough (TB?), water
extracts of dried leaves for colic, crushed leaves for
rheumatism and joint pain [35]; hot water decoctions
of roots for diarrhea, dysentery and ankylostomiasis
[37]; Pounded roots cooked in porridge for
hookworms and dysentery, ground roots cooked
and applied to wounds, root decoctions for
stomach-ache, cough, pneumonia, vomiting, stomach
ulcers and diarrhea, leaf infusions for cough, stem
bark infusion for leprosy [80].
Roots, leaves and stem bark made into decoctions or
mixed in maize porridge for diarrhea
and stomach tumors [78].
Stem bark and leaf extracts inhibitory against several
bacteria [81,82]; Fruit, stem bark and root extracts show
good antibacterial potential.
Triterpenoids from leaves evaluated for anti-Candida
effects; terminolic acid was found to be the most active
compound. SAR: oleanane and ursane type triterpenoids
were the most active ones [54].
We found that extracts of stem bark and roots inhibit
the growth of Mycobacterium smegmatis, the BuOH fraction
of the roots being especially active (IZ 23 mm).*
Triterpenoids and saponins from the leaves [47]; Three
unidentified antimicrobial compounds were isolated from
the leaves and stem bark [82]; Ursolic acid, maslinic acid,
2α,3β-dihydroxyurs-
12-en-28-oic acid, 6β-hydroxymaslinic acid and terminolic
acid from leaves [54].
A root butanol extract contained six ellagic acid derivatives
including methyl-ellagic acid xyloside, di-methyl-ellagic
acid xyloside
and 3,3′-Di-O-methyl-4-O-(n′′-O-galloyl-β-d-xylopyranosyl)
ellagic acid, fifteen ellagitannins including punicalagin
and nine gallotannins including hexagalloylglucose.*
Our results presented in this paper *; AI, activity index in % activity of rifampicin; MIC, minimum inhibitory concentration; IZD, inhibition zone diameter in mm; TB, tuberculosis; TM,
traditional medicine. In brackets the voucher numbers of the collected specimen used in this study. Plant uses for symptoms related to TB marked with bold text.
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2. Results
2.1. Antimycobacterial Effects of Extracts and Fractions
Altogether, 26 extracts and solvent partition fractions from Combretum psidioides, C. padoides and C.
zeyheri, used for the treatment of bacterial infections and even cough (C. zeyheri) in African traditional
medicine (Table 1), were screened for their growth inhibitory effects against Mycobacterium smegmatis
ATCC 14468. M. smegmatis has been found to be rather resistant to rifampicin [83]. Therefore, inhibitory
effects against this bacterial strain could indicate that the extracts and fractions also to a certain extent
might inhibit rifampicin resistant strains of Mycobacterium tuberculosis. Moreover, M. smegmatis has
some virulence genes in common with M. tuberculosis, and thus serves as a good model bacterium [84].
The results regarding the antimycobacterial activity of crude methanol extracts and their solvent
partition fractions of the investigated species of Combretum spp. are shown in Tables 2 and 3.
Table 2. Antimycobacterial effects of extracts and their solvent partition fractions of species of Combretum
collected in Tanzania by the first author in spring 1999. Results obtained with an agar diffusion method.
Activity index (AI) in relation to rifampicin.
Combretum Species, Extracts and Fractions M. Smegmatis ATCC 14468 AI
C. padoides S Cr 26.5 ± 0.5 0.50
C. padoides WI 18.0 ± 2.0 0.34
C. padoides BuOH 26.5 ± 0.5 0.50
C. padoides CHCl3 17.5 ± 0.5 0.33
C. zeyheri S Cr 12 20.5 ± 0.5 0.39
C. zeyheri WI 0.0 0.00
C. zeyheri Ws 17.0 ± 3.0 0.32
C. zeyheri BuOH 19.0 ± 2.0 0.36
C. zeyheri CHCl3 14.0 ± 0.0 0.27
C. zeyheri S Cr 43 21.0 ± 0.0 0.40
C. zeyheri WS 18.5 ± 0.5 0.35
C. zeyheri WI 17.5 ± 0.5 0.33
C. zeyheri BuOH 20.5 ± 0.5 0.39
C. zeyheri CHCl3 0.0 0.00
C. zeyheri R Cr 33 16.0 ± 0.8 0.30
C. zeyheri WS 0.0 0.00
C. zeyheri WI 16.0 ± 1.6 0.30
C. zeyheri BuOH 23.0 ± 1.6 0.44
C. zeyheri CHCl3 14.0 ± 0.0 0.27
C. psidioides S Cr 29.00 ± 0.5 0.53
C. psidioides BuOH 21.5 ± 2.0 0.41
C. psidioides WI 0.0 0.00
C. psidioides CHCl3 25.5 ± 0.7 0.48
C. psidioides L Cr 0.0 0.00
Rifampicin 52.5 ± 0.5 1.00
R, roots; S, stem bark; F, fruits; L, leaves; Cr, crude methanol extract; WS, aqueous fraction; WI, aqueous insoluble
fraction; BuOH, butanol fraction; CHCl3, chloroform fraction. 12, 43 and 33 are different individuals of C. zeyheri.
Two hundred µL extracts/fractions (50 mg/mL) and rifampicin (10 mg/mL) were applied on filter paper discs.
Diameter of inhibition zones (IZD) in mm as mean of triplicates (n = 3) ± SEM of three experiments. Most promising
results indicated by bold text and the best result underlined.
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Table 3. Minimum inhibitory concentrations and total antimycobacterial activities of crude methanol
extracts of Combretum spp. and their solvent partition fractions against Mycobacterium smegmatis.
Pure compounds, such as corilagin and ellagic acid, representative for compounds occurring in
the extracts were also tested.
Extracts M. Smegmatis ATCC 14468 Total Activity (mL/g)
C. psidioides stem bark:
crude methanol extract 625 (IC94) 313.44
butanol soluble fraction 2500 (IC95) 98.76
chloroform soluble fraction 2500 (IC90) 22.89
C. padoides stem bark:
crude methanol extract 1250 (IC93) 85.12
butanol soluble fraction 2500 (IC97) 190.12
Pure compounds:
Corilagin * 1000 (IC94)
Ellagic acid ** 500 (IC98)
Rifampicin 3.90 (IC91)
In brackets the mean percentage of the bacterial growth inhibited by indicated concentration and resulting in no
visible growth (IC, inhibitory concentration). * In butanol extract of C. psidioides; ** Not present in the extracts as
such but as ellagic acid glycosidic derivatives. The total antimycobacterial activity (mL/g) is and indication on
the degree to which 1 g of an extract can be diluted without losing its antimycobacterial activity and is calculated as:
extraction yield in mg extracted material/mg plant powder divided to the MIC of the extract [83].
Combretum psidioides gave the best growth inhibitory effects against M. smegmatis of the three
species of Combretum used in this investigation. The lowest MIC of 625 µg/mL was shown by a methanol
extract of the stem bark of this species. This extract also gave a large inhibition zone diameter of 29.0
mm (Tables 2 and 3) as well as a good total antimycobacterial activity of 313.44 mL/g (Table 3). The total
antimycobacterial activity is dependent on the extraction yield and the MIC of a plant extract, and is
calculated as the ratio between the yield (in mg/g) and the MIC (in mg/mL) [84]. Moreover, we also
found that chloroform and butanol extracts of the stem bark of C. psidioides were growth inhibitory
against M. smegmatis, both giving MIC values of 2500 µg/mL and inhibition zone diameters of 25.5
and 21.5 mm, respectively (Tables 2 and 3). In addition, although the MIC of the butanol fraction of C.
psidioides was 2500 µg/mL, this extract was the most effective of the investigated extracts and fractions
to inhibit the growth of M. smegmatis at lower concentrations and at 312 µg/mL, this extract resulted in
an 84% growth inhibition.
Antimycobacterial effects were observed for methanol and butanol extracts of the stem bark of
C. padoides, and both showed inhibition zone diameters of 26.5 mm and an activity index of 0.50 in
comparison to rifampicin (IZD 52.5 mm) (Table 2). The MIC value of the crude methanol extract was
1250 µg/mL and for the butanol extract 2500 µg/mL (Table 3) and the growth inhibition of both extracts
was dose-dependent for concentrations ranging down to 312 µg/mL (Figure 1). For both the crude
methanol and butanol extracts, the growth inhibition was stronger at 78 µg/mL when compared to 156
µg/mL (Figure 1). Although the MIC of the butanol extract was higher than the MIC for the methanol
extract, the butanol extract gave stronger growth inhibition than the methanol extract at concentrations
below 625 µg/mL, and at 78 µg/mL still 51% of the growth was inhibited (Figure 1).
Compared to C. padoides and C. psidioides, C. zeyheri gave only mild antimycobacterial effects
and a root butanol extract gave the best effect (IZD 23.0 mm) (Table 2).
In comparison to the plant extracts, rifampicin gave an inhibition zone diameter of 52.5 mm
and a MIC of 3.9 µg/mL (Table 2, Table 3, Figure 1).
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Figure 1. Dose-response bars as percentage inhibition of growth of (A) the crude methanol extract
and (B) the butanol extract of C. padoides, and (C) rifampicin. Tests were performed in triplicates ±SD.
2.2. Phytochemistry
2.2.1. Combretum Psidioides
Based on the growth inhibitory results of both the methanol and the butanol extracts of the stem bark
of C. psidioides, a butanol extract was chosen for phytoche ical analysis on its polyphenolic composition
using HPLC-DAD and UHPLC/QTOF-MS. Although showing a higher MIC than the methanol
extract, the butanol extract was chosen for this analysis since the methanol extract contained a high
concentration of condensed tannins that could interfere with the analysis (Figure S1). However, in
terms of the ellagitannins and the ellagic acid derivatives composition, the butanol and methanol
extracts contained the same compounds (Supplementary Figure S1). The results of the HPLC-DAD
and UHPLC/QTOF-MS analysis of the butanol extract of the stem bark of C. psidioides are shown in
Table 4. 3′-O-methyl-4-O-(β-d-xylopyranosyl)ellagic acid ( [M-H]− at m/z 447.0574) was present at Rt
19.85 min (Table 4, Figure 2d). In addition, three other ellagic acid derivatives were identified at Rt
17.56, 18.93, and 24.92 min, showing two clear UVλ absorbance maxima, the first at 254 and the other
at 362–380 nm, which is typical for this class of compounds [85]. UHPLC/QTOF-MS data revealed
the molecular masses of three tentatively identified ellagitannins; corilagin at Rt 12.24 min ([M-H]− at
m/z 633.0750), punicalagin at Rt 14.96 min ([M-H]- at m/z 1083.5410, ) and sanguiin H-4 at Rt 8.21 min
([M-H]− at m/z 633.0746) (Table 4, Figure 3a,b). The thirteen unknown ellagitannins could be identified
as ellagitannins based on their UVλ absorption spectra, demonstrating three absorption maxima,
characteristic for ellagitannins (Table 4, Figure 3c,d). Epigallocatechin gallate (MW 458.0843) at Rt 9.43
min was tentatively identified according to computer compound libraries available and characteristics
such as UVλ absorption maxima data as well as HPLC retention time (Table 4, Figure 3e). To the best
of our knowledge, this tea polyphenol has not been reported before in the genus Combretu .
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Table 4. Polyphenolic profile of a butanol extract of the stem bark of Combretum psidioides. Data recorded using HPLC-DAD and UHPLC coupled to quadrupole time
of flight mass spectrometry. Combretastatin B-2 was identified using GC-MS*.
Compounds Molecular Formula Rt HPLC-DAD or GC*(min) Rt UHPLC (min)
Measured [M-H]− (m/z)
or * GC-MS Exact Mass (calc.) ppm Value UVλmax (in MeOH) Peak Area % (280 nm)
Gallic acid C7H6O5 1.636 1.334 169.0149 170.0213 8.2834 216, 272 9.2848
Flavonoid? 1.933 210, 224, 278 0.1800
Protocatechuic acid C7H6O4 3.718 2.733 153.0196 154.0264 6.5352 210, 218, 260, 294 4.6595
O-hydroxycinnamic acid like 4.628 210, 230, 280, 310 0.7723
Unknown ellagitannin 7.187 214, 258, 376
Unknown ellagitannin 7.731 216, 260, 378 4.0268
Sanguiin H-4 C27H22O18 8.208 4.448 633.0746 634.0798 4.1070 216, 258, 376 5.7862
Gallotannin 8.979 258, 218 0.1717
Epigallocatechin gallate C22H18O11 9.427 458.0843 210, 276 0.5409
Unknown ellagitannin 9.673 216, 258, 378 2.5987
1,6-Di-O-galloyl-β-d-Glucose C20H20O14 10.022 4.700 483.0801 484.0846 6.8312 216, 276 2.7681
Unknown ellagitannin 10.406 214, 252, 384 0.1968
Unknown ellagitannin 10.778 216, 260, 374 4.4198
Galloylglucose 10.975 216, 276 2.0395
Unknown ellagitannin 11.178 214, 260, 381 0.0556
Unknown ellagitannin 11.454 218, 256, 378 0.8819
Corilagin C27H22O18 12.244 633.0750 634.0798 4.7388 215, 258, 380 5.7058
Epigallocatechin like (flavan-3-ol) 13.391 210, 282, 320 0.5197
Combretastatin B-2 C17H20O5 *13.489 *304 304.1311 6.9049
Galloylglucose 14.281 216, 276 4.2740
β-Punicalagin C48H28O30 14.956 5.427 1083.1541 1084.0654 25.6045 218, 256, 380 6.9297
Epigallocatechin like 17.368 210, 284
Ellagic acid derivative 17.565 254, 380 3.3214
Gallotannin 17.591 216, 282
Ellagic acid derivative 18.935 254, 362 0.3382
3′-O-methyl-4-O-(β-d-xylopyranosyl)
ellagic acid (main compound) C20H16O12 19.846 8.201 447.0574 448.0636 3.5790 254, 364 8.4825
Gallotannin (not PGG) 21.184 939.1000 214, 280 0.1463
Unknown ellagitannin 21.815 218, 248, 368 0.5505
Ellagic acid derivative 24.922 254,362 3.1564
Unknown ellagitannin 26.444 210, 264, 398 0.0953
Unknown ellagitannin 27.163 218, 254, 360 0.3147
Unknown ellagitannin 28.605 218, 256, 362 2.0192
Unknown ellagitannin 31.560 216, 256, 360 1.8907
Unknown ellagitannin 3.688 218, 256, 360 0.9801
Hexagalloylglucose C48H36O30 38.299 1092.1278 218, 280 0.1879
Rt (min), retention times obtained from HPLC-DAD and UHPLC-DAD; [M-H]−, base ion at negative mode. Percentage peak area from HPLC-DAD chromatograms was acquired at 280
nm. PGG, pentagalloylglucose. * results obtained with GC-MS.
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Stilbenoid compounds are known to be present in Combretum spp. [61–68]. Stilbenes in the methanol
extract of the stem bark of C. psidioides could contribute to the antimycobacterial effects of this extract
(MIC 625 µg/mL). Therefore, a GC-MS analysis was made to study the stilbenoid composition of this
extract. This analysis resulted in the characterization of combretastatin B-2 (exact calculated mass for
C17H20O5, MW 304.13107) and its dihydrostilbene derivatives (Figure 4, Table 4). To the best of our
knowledge, combretastatin B-2 has not been described before in C. psidioides, although a number of
other bibenzyls were characterized from the heartwood of this plant by Letcher & Nhamo [63].
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2.2.2. Combretum Padoides
Since the HPLC-DAD chromatograms of the methanol and butanol extracts of the stembark
of C. padoides were almost identical, but with the butanol part showing a slightly cleaner profile
(Figure S2), we chose the butanol part for UHPLC/QTOF-MS analysis. In addition, although the MIC
was lower for the methanol extract, the IC50 value was lower (<312 µg/mL) for the butanol part,
which wa also a criterium for cho sing this extract for the phytochemic l analysis. The results of
this a alysis ar shown in Table 5. Altogether wenty-six ellagitannins were t ntatively dentified
based on their retention times, mass spectrometric data and characteristic UV absorbance spectra
(Figure 5). The ellagitannin present in the highest concentration, at Rt 10.90 min, resembled punicalagin,
giving a [M-H]− molecular ion at m/z 1083.0587. The retention time of this ellagitannin (10.90 min)
was, however, not in agreement with the retention time that we have found before for β-punicalagin
(Rt 14.95–15.64 min). Thus, this ellagitannin could be punicacortein D, with the molecular formula
C48H28O30, identical to punicalagin, but with a shorter retention time in HPLC-DAD, compared to
punicalagin [86]. Punicacortein D has been found in only one other species of the family Combretaceae,
Combretum aculeatu [86]. However, there is also a possibility that this llagitannin at Rt 10.90 min
would be the α-anom r of punicalagin, wh ch is otherwise ident cal to β-punicalagin to its mass
spectrometric data, but has a shorter HPLC-retention time. Moreover, the α- and β- anomers of
punicalagin differ by slight shifts in their UVλ absorbance maxima, due to differences in the position
of the OH-group and the H-atom linked to the anomeric C-1 atom [86,87]. However, in our analysis,
it was impossible to distinguish α-punicalagin from punicacortein D.
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Table 5. Polyphenolic profile of a butanol extract of the stem bark of Combretum padoides. Data recorded using HPLC-DAD and UHPLC coupled to quadrupole time of
flight mass spectrometry.
Compounds Molecular Formula Rt HPLC-DAD (min) Rt UHPLC (min) Measured [M-H]− (m/z) Exact Mass (calc.) ppm Value UVλmax (in MeOH) Peak Area % (280 nm)
1-O-galloyl-β-d-glucose (syn.
β-glucogallin) C13H16O10 1.577 331.0685 332.0738 7.5514 216, 276 0.1894
Gallic acid C7H6O5 1.763 1.306 169.0157 170.0213 13.0167 216, 272 1.2354
Ellagitannin 3.245 215, 260, 380 1.8848
Ellagitannin 7.815 3.170 466.0264 214, 258, 380 3.1453
Ellagitannin 8.408 216, 258, 376 1.4324
Ellagitannin 8.829 3.387 1083.0591 216, 256, 374 8.3917
Gallotannin 9.370 216, 252 2.6083
Ellagitannin 9.740 210, 258, 380 0.7464
Corilagin derivative C27H22O18 10.114 3.768 633.0750 634.0798 4.7388 216, 258, 379 10.9106
Ellagitannin 10.413 220, 256, 374 0.4238
α-Punicalagin anomer or
Punicacortein D C48H28O30 10.903 3.853 1083.0587 1084.0654 1.0156 216, 260, 376 14.9380
Ellagitannin 11.382 3.903 1083.0581 216, 258, 376 3.9407
Ellagitannin 11.764 216, 258, 380 0.1157
Ellagitannin 12.073 218, 258, 378 4.6576
Ellagitannin 12.385 224, 256, 374 0.7334
Ellagitannin 12.619 210, 260, 382 0.2170
Ellagitannin 12.858 214, 256, 378 2.7210
Unknown 13.373 214, 248, 292 0.1398
Flavonoid; Ampelopsine like 13.643 210, 280 0.5307
Ellagitannin 14.054 218, 258, 368 0.1152
Ellagitannin 14.500 220, 260, 376 0.8036
Flavonoid 15.137 210, 276, 370 0,9277
Ellagitannin 15.693 216, 256, 380 5.3916
Ellagitannin 16.015 210, 256, 364 0.2770
Ellagitannin 16.219 216, 260, 378 0.7760
Ellagitannin 16.849 216, 284, 382 0.3067
Ellagitannin 17.668 218, 260, 378 0.8513
Gallotannin 17.975 218, 280 0.2328
Ellagic acid derivative 18.556 254, 380 0.4644
Stilbene like compound? 18.809 210, 235, 382 0.9999
Gallotannin 18.991 210, 280 0.4259
Ellagic acid derivative 19.960 254, 362 0.2292
Ellagitannin 20.253 4.502 1085.0719 210, 254, 362 0.5726
Ellagic acid arabinoside C19H14O12 20.792 8.316 433.0391 434.0480 -2.5402 254, 362 1.6928
3′-O-methyl-4-O-(β-d-xylopyranosyl)
ellagic acid C20H16O12 21.055 8.616 447.0564 448.0636 1.3421 254, 368 4.4746
Gallotannin (not PGG) 22.163 214, 284 0.1343
Ellagic acid derivative 26.258 254, 360 1.5195
Ellagitannin 28.596 216, 254, 362 0.1066
Ellagitannin 30.121 216, 254, 362 1.5374
Ellagitannin 33.134 216, 256, 360 2.2061
Ellagitannin 36.269 218, 256, 362 0.8344
Rt (min), retention times obtained from HPLC-DAD and UHPLC-DAD; [M-H]−, base ion at negative mode. Percentage peak area was acquired from HPLC-DAD chromatograms at 280 nm.
Antibiotics 2020, 9, 459 12 of 30tibiotics , , x FOR PEER REVIEW 7 f 5 
 
Figure 5. UVλ absorption spectra of ellagitannins in a butanol stem bark extract of Combretum padoides. 
(a) A corilagin like ET; (b,c) unknown ellagitannins; (d) punicalagin like ET (either α-punicalagin or 
punicacortein D); (e) an unknown ellagitannin 
We also found that the stem bark of C. padoides contains high concentrations of another 
ellagitannin at Rt HPLC-DAD 10.11 min, showing a [M-H]− molecular ion at m/z 633.0750, identical 
to that of corilagin (Table 5), [88]. The retention time of this ellagitannin however was different from 
that of corilagin, which we have found at Rt 12.52 min in Terminalia laxiflora roots [89] as well as in 
this investigation in Combretum psidioides stem bark at Rt HPLC-DAD 12.24 min (Table 4). Thus, this 
ellagitannin is tentatively suggested to be an isomer of corilagin. In addition to the mentioned 
ellagitannins, we identified the masses of four unknown ellagitannins; an ellagitannin at Rt 7.81 min 
gave a [M-H]− molecular ion at m/z 466.0264, a second one at tR 8.83 min gave a [M-H]− molecular 
ion at m/z 1083.0591, a third one at Rt 11.38 min gave a [M-H]− molecular ion at m/z 1083.0581 (co-
eluting with punicacortein D or α-punicalagin at Rt 10.90 min) and a fourth ET at Rt 20.25 min 
showing a [M-H]− molecular ion at m/z 1085.0719 (Table 5). When conducting a literature search for 
possible ellagitannins with molecular masses of 1086 occurring in Combretum spp., we did not find 
any matches. Instead, we found a reference of an ellagitannin giving a [M-H]− molecular ion at m/z 
1085, found in strawberry fruits [90]. The molecular structure of this ellagitannin was not elucidated, 
however. 
We found five ellagic acid derivatives, at Rt 18.55, 19.96, 20.24, 21.05, and 26.26 min, in the stem 
bark of C. padoides, showing two peaks of UV absorbance, one at 254 and the other at 362–380 nm, 
typical for ellagic acid based molecules (Table 5, Figure 2e,f). To the best of our knowledge, ellagic 
acid arabinoside (Rt 20.79 min, [M-H]− at m/z 433.0391) and methyl ellagic acid xyloside (Rt 21.05 
min, [M-H]- at m/z 447.0564) have not been reported before in C. padoides. 
Moreover, based on their UV absorption maxima, four gallotannins were identified in the stem 
bark of C. padoides, as well as their precursor, 1-O-galloyl-β-D-glucose (β-glucogallin, Rt 1.58 min) 
giving a [M-H]− molecular ion at m/z 331.0685) (Table 5). Glucogallin is known from Quercus spp. [91] 
and from Emblica officinalis [92], but to the best of our knowledge not from Combretum spp. 
  
Figure 5. λ absorption spectra of ellagitannins in a butanol ste bark extract of Combretu padoides.
(a) corila i li e ; ( ,c) o ella ita i s; ( ) icala i li e (eit er - icala i or
icac rtei ); (e) a ella ita i .
also found that the st m bark of C. padoides contains high concentrati s of another ellagitannin
at Rt HPLC-DAD 10.11 min, showing a [M-H]− molecular ion at m/z 633.0750, identical to that of
c ril gin (Table 5), [88]. The retention time f this ellagitannin however was different rom that of
corilagin, which e have found at Rt 12.52 min in Terminalia laxiflora roots [89] as well as in this
investigation n Combretum psidio es stem bark at Rt HPLC-DAD 12. 4 min (Table 4). ,
is of corilagin.
fi
[ - ]− l ion at m/z 466.0264, a second one at tR 8.83 min gave a [M-H]− molecular ion
at m/z 1083.0591, a third one at Rt 11.38 min gave a [M-H]− molecular ion at m/z 1083.0581 (co-eluting
with punicacorte n D or α-punicalagi at Rt 10.90 min) and a fourth ET at Rt 20.25 min showing
a [M-H]− molecular ion at m/z 1085.0719 (Table 5). When conducting a literature s arch for possible
ellagitannins with molecular masses of 1086 occurring in Combretum spp., we did not find any matches.
I stead, w found reference of n llagitannin givin a [M-H]− molecular ion at m/z 1085, found in
strawberry fruits [90]. The molecular structur of thi ellagitannin was not elucidated, however.
W found five ellagic acid derivatives, at Rt 18.55, 19.96, 20.24, 21.05, and 26.26 min, in the stem
bark of C. padoides, showing two pe ks of UV absorbance, one at 254 and the other at 362–380 n ,
typical for ellagic acid based m lecule (Table 5, Figure 2e,f). To the best of our knowledge, ellagic
acid rabinoside (Rt 20.79 min, [M-H]− at m/z 433.0391) and methyl ellagic acid xyloside (Rt 21.05 min,
[M-H]- at m/z 447.0564) have not been reported before in C. padoides.
Moreover, based on their UV absorption maxima, ur gallot nnin were identified in the stem
bark of C. padoide , as well as their precursor, 1-O-g ll yl-β-d-glucose (β-glucogallin, Rt 1.58 min)
giving a [M-H]− molecular ion at m/z 331.0685) (Table 5). G ucogal in is known fr m Quercus spp. [91]
and from Emblica fficinalis [92], but to the best of our knowled e not from Combretum spp.
Antibiotics 2020, 9, 459 13 of 30
2.2.3. Combretum Zeyheri
Since the root part of C. zeyheri gave slightly better growth inhibitory effects than the stem
bark, this part was chosen for a phytochemical analysis on its polyphenols. Moreover, C. zeyheri
has not been analysed before for its polyphenolic composition. Our UHPLC/QTOF-MS analysis of
the butanol fraction of the roots demonstrated that a gallotannin at Rt 15.008 min, showing a [M-H]−
molecular ion at m/z 765.0566 was the main compound in this extract, giving a peak area of 20.08%
(at UV 280 nm, Table 6, Figure 2g). C. zeyheri contained more gallotannins and condensed tannins than
C. psidioides and C. padoides. Altogether eight gallotannins and three procyanidins were found based
on the UVλ absorption maxima spectra of these compounds. UVλ absorption maxima peaks with two
shoulders, one at 216 nm and another at 258–278 nm, could be seen for the gallotannins (Figure 2g),
whereas the condensed tannins gave two absorption maxima at 212 and at 272–276 nm (Figure 3e).
Moreover, fourteen ellagitannins were identified based on their characteristic UVλ absorption maxima
spectra as well as retention times. Of these ellagitannins, punicalagin at Rt 15.64 min ([M-H]− at m/z
1083.0574) was present in the highest concentrations. In addition, the masses of three unknown
ellagitannins were determined; an ellagitannin at Rt 34.99 min ([M-H]− at m/z 763.0788), another one
containing both ellagic and gallic acid units (ellagigallotannin) at Rt 36.93 min ([M-H]− at m/z 765.0566)
and a third at Rt 39.96 min ([M-H]− at m/z 817.4212). Moreover, five ellagic acid derivatives were present,
among which methyl ellagic acid (Rt 29.92 min, ([M-H]− at m/z 447.0566), dimethyl-ellagic acid-xyloside
(Rt 34.24 min, [M-H]− at m/z 461.0741), and 3,3′-Di-O-methyl-4-O-(n′′-O-galloyl-β-d-xylopyranosyl)
ellagic acid (Rt 36.26 min, [M-H]− at m/z 613.0849) were tentatively identified.
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Table 6. Polyphenolic profile of a butanol extract of the roots of Combretum zeyheri. Data recorded using HPLC-DAD and UHPLC coupled to quadrupole time of flight
mass spectrometry.
Compounds Molecular Formula Rt HPLC-DAD (min) Rt UHPLC (min) Measured [M-H]− (m/z) Exact Mass (calc.) ppm Value UVλmax (in MeOH) Peak Area % (280 nm)
Gallic acid C7H6O5 1.760 1.173 169.0140 170.0213 2.9583 216, 272 1.1995
Gallic acid derivative 2.191 216, 274 0.6905
Protocatechuic acid C7H6O4 3.865 2.593 153.0198 154.0264 218, 220, 260, 294 0.1245
Cinnamic acid like 7.025 0.1205
Gallotannin or gallic acid derivative 8.516 216, 274 3.3768
Corilagin isomer 8.835 216, 254, 374 2.8165
Gallotannin 9.325 216, 258 0.1997
Ellagitannin 10.080 218, 258, 378 0.0607
Gallotannin 10.481 216, 275 3.2150
Ellagitannin 11.190 216, 256, 378 0.2296
Gallotannin 11.486 216, 277 2.2688
Ellagitannin 11.984 220, 256, 378 0.3862
Ellagitannin 12.804 216, 256, 380 2.2389
Eriodictyol like 13.899 210, 279 2.2785
Ellagitannin 14.531 222, 258, 380 0.1015
Gallotannin 15.008 5.352 647.0894 216, 276 20.0817
Punicalagin C48H28O30 15.645 5.485 1083.0574 1084.0654 −0.1847 216, 256, 381 4.3927
Batatasin like 16.068 210, 272 0.0939
Ellagitannin 16.562 256, 372 0.0601
Salidrosid and arbutin like 17.497 217, 274, 276, 298 0.7553
Ellagic acid derivative 18.559 5.718 435.1310 254, 380 0.4557
Lignan? 19.014 210, 272 2.3806
Lignan? 19.462 210, 274 0.0977
Lignan? 20.178 210, 276 3.1006
Ellagic acid derivative 20.773 5.818 581.1903 254, 362 0.4712
Procyanidin B-3 like 23.022 212, 274 2.8707
Ellagic acid derivative 24.693 8.033 435.1310 250, 366 1.4412
Ellagitannin 26.230 210, 254, 360 1.2651
Lignan? 26.778 210, 274 1.3692
Procyanidin B-3 like 27.670 212, 276 1.0954
Stilbene or lignan? 27.956 212, 264 0.8470
Procyanidin B-3 like 28.803 212, 272 1.2008
Methyl-ellagic acid xyloside C20H16O12 29.922 8.582 447.0566 448.0636 1.7895 210, 274 1.5613
Ellagitannin 31.578 0.0677
Ellagitannin 32.116 216, 256, 366 0.1269
Ellagitannin 33.103 216, 256, 360 0.7444
Di-methyl-ellagic acid xyloside C21H18O12 34.243 9.931 461.0741 462.0792 5.8559 251, 366 0.9611
Ellagitannin 34.998 10.192 763.0788 226, 268, 370 0.2394
3,3′-Di-O-methyl-4-
O-(n′′-O-galloyl-β-
d-xylopyranosyl) ellagic acid
C28H22O16 36.257 12.312 613.0849 614.0900 4.4039 218, 256, 358 0.2287
Gallotannin or ellagitannin according to
the UV abs max 36.931 12.829 727.0566; 765.0566 216, 252, 366 1.1001
Hexagalloylglucose C48H36O30 39.583 1092.1278 216, 278 5.0497
Ellagitannin 39.956 13.994 817.4212 210, 252, 363 0.4127
Gallotannin Ellagitannin? 44.414 17.000 725.4118 216, 274 0.3647
Rt (min), retention times obtained from HPLC-DAD and UHPLC-DAD; [M-H]−, base ion at negative mode. Percentage peak area was acquired from HPLC-DAD chromatograms at 280 nm.
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3. Discussion
3.1. Antimycobacterial Effects of the Extracts of the Studied Species of Combretum in Relation to Other Studies
on the Antimycobacterial Effects of Combretum spp.
A number of studies demonstrate that extracts of Combretum species possess antimycobacterial
effects. For example, Combretum comosum was found to give growth inhibitory effects against M.
phlei [93]; C. brassii gave antimycobacterial effects against M. tuberculosis (MIC 1250 µg/mL) [94]; extracts
from C. platypetalum and C. imberbe gave MIC values of 63–500 µg/mL against M. smegmatis and M.
aurum [95]; acetone extracts of the leaves of C. hereroense gave a MIC value of 470 µg/mL against M.
smegmatis [96]; acetone extracts of the leaves of C. schumannii gave a MIC value of 313 µg/mL against
M. madagascariense and stem bark dichloromethane and root ethanol extracts were effective against M.
indicuspranii [28]; C. hartmannianum leaf ethanol extracts showed strong growth inhibition against M.
aurum A+ with a MIC value of 190 µg/mL [97] and ethanol extracts of the leaves, bark and root of C.
kraussii gave MIC values of 195 µg/mL against M. aurum A+ [98,99].
In our investigation, methanol and butanol extracts of Combretum psidioides, C. padoides, and C.
zeyheri were found to give MIC values from 625 to 2500 µg/mL against M. smegmatis. To the best of
our knowledge, C. padoides and C. psidioides have not been studied before for their growth inhibitory
effects against M. smegmatis. In addition, the roots of C. zeyheri have not been explored before for their
antimycobacterial effects.
Contrary to our result, Luo et al. [100] reported that stem bark extracts of C. zeyheri are not
antimycobacterial against M. smegmatis and M. tuberculosis. However, Luo et al. [100] defined all
extracts as not active with MIC values exceeding 125 µg/mL and the MIC results for C. zeyheri were not
shown. Moreover, Magwenzi et al. [95] found that a leaf extract of C. zeyheri was not active against
Mycobacterium smegmatis. This could be due to differences in growth inhibitory activities between
different organs in C. zeyheri, so that the stem bark and roots might contain more and perhaps different
active compounds than the leaves, since we have seen that especially butanol and methanol extracts of
the stem bark and roots of C. zeyheri give growth inhibitory effects against M. smegmatis. However,
an alkaloid enriched leaf extract of C. zeyheri was found to inhibit the growth of M. smegmatis with
a MIC value of 125 µg/mL and the growth inhibition was concentration- and time dependent [101].
Moreover, the same authors also discovered that this alkaloid extract of C. zeyheri was a potent inhibitor
of efflux pumps in M. smegmatis. Thus, C. zeyheri (and other African Combretum spp.) might contain
a number of alkaloids with antimycobacterial properties yet to be explored.
3.2. Ellagitannins in the Species of Combretum and Their Suggested Impact on the Antimycobacterial Effects of
These Species
Although some Combretum spp. have been found to be rich in ellagitannins and their derivatives
as well as other hydrolysable tannins [13,74,86] (Figure 6), these compound categories and their
possible potential role as antimicrobials have not been studied in detail in this genus. This could partly
be due to the poor bioavailability of ellagitannins, although they could have potential as topically
administered antimicrobials or in the gut as well as in combinations with conventional antibiotics or
via their metabolites, the urolithins. Among the few studies available on ellagitannins in Combretum
spp. is the study of Jossang et al. [74], who characterized 2,3-(S)-hexahydroxydiphenoyl-d-glucose
(MW 482.34), punicalin (MW 782.52), punicalagin (MW 1084.71), and combreglutinin (MW 1236.837)
from the leaves of the West-African species, Combretum glutinosum. Combreglutinin is composed of
one extra galloyl group compared to punicalagin (Figure 6).
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In our study, especially butanol and methanol extracts of the stem bark of C. psidioides and C. padoides
and the roots of C. zeyheri, enriched in ellagitannins and gallotannins and their monomers (ellagic acid
and gallic acid derivatives), gave good antimycobacterial effects. Thus, the antimycobacterial effects
of these extracts are suggested to be partly due to these compound classes, and for the ellagitannins
perhaps most likely via their urolithin metabolites [86]. This is supported by Coulidiati et al. [102]
who demonstrated that tannins, and especially hydrolysable tannins (ellagitannins and gallotannins),
predominate in n-butanol extracts of Combretum sericeum and these compounds were suggested to be
responsible for the antimicrobial activity of the extracts.
We found that punicalagin (Figure 6) is present in the stem bark of Combretum psidioides and in
the roots of C. zeyheri. To the best of our knowledge, there are no previous reports on the occurrence of
punicalagin in the mentioned Combretum species. Previously, apart from C. glutinosum, punicalagin
was found in Combretum molle [13] and both the α- and β-punicalagin anomers were characterized
in Combretum aculeatum [86]. Punicalagin isolated from the stem bark of C. molle gave growth
inhibitory effects against M. tuberculosis typus humanus ATCC 27,294 and against a clinical strain
with MIC values of 600 and 1200 µg/mL, respectively [13] and was the first ellagitannin reported to
possess antimycobacterial effects. We therefore suggest that part of the antimycobacterial activities
of the butanol extracts of C. psidioides stem bark and C. zeyheri roots, reported in this paper, might be
due to this ellagitannin, and perhaps in combinations with the other ellagitannins in these extracts.
However, again, these activities are in vitro, and further studies should be performed on urolithins
resulting from the metabolism of punicalagin, and their effects on mycobacterial strains.
Our study revealed the occurrence of corilagin and sanguiin H-4 in Combretum psidioides
and a corilagin like ellagitannin in C. padoides stem bark (Figure 6). To the best of our knowledge,
corilagin and/or its isomers and sanguiin H-4 have not been found in Combretum species earlier. Corilagin
has been reported to occur in various species of the closely related genera Terminalia [86,103,104]
and Lumnitzera (Combretaceae) [105]. Corilagin was found to give good growth inhibitory effects
against S. aureus with a MIC value of 25 µg/mL [106], and to inhibit the growth of methicillin resistant
S. aureus [107,108]. Moreover, corilagin increased membrane permeability in E. coli and C. albicans [109].
In addition, corilagin gave bactericidal effects in vitro against Klebsiella pneumoniae [110] and inhibited
the growth of Acinetobacter baumanii [111]. Interestingly, corilagin was found to potentiate the activity
of β-lactam antibiotics 100–2000-fold against methicillin-resistant S. aureus via inhibition of the activity
of penicillin binding protein 2 [108,112]. However, in our screenings on the effects of pure corilagin on
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M. smegmatis growth, we found that this ellagitannin showed only weak growth inhibition (MIC 1000
µg/mL, Table 3). This could imply that the ellagitannins in the Combretum-extracts work together with
each other and with other secondary defense compounds to produce antimycobacterial, and perhaps
synergistic or additive effects in combinations. Further investigations on the effects of ellagitannins
in the Combretum species studied in this investigation and their urolithin metabolites, both alone
and in combinations with isoniazid and rifampicin, on the growth of M. smegmatis and M. tuberculosis
are warranted.
Since traditional medicines with Combretum spp. as ingredients are often prepared as decoctions
or macerations, this means that polar ellagitannins and other polyphenols, extracted with hot
or cold water are important components in them. Macerations of the stem bark of C. psidioides,
enriched with polyphenols, are specifically used for the treatment of diarrhea [34] and decoctions of
the roots, leaves and stem bark of C. zeyheri are used for cough that could be related to TB [35,37,38],
which implies that these species and preparations contain antibacterial (and antimycobacterial)
compounds. Interestingly, we have seen that the chromatographic profiles of butanol and methanol
extracts of the studied Combretum spp. resembled those of the corresponding water extracts, with
ellagitannins as the main compounds also in water extracts (Figure S3). This could imply that decoctions
and macerations of C. psidioides, C. padoides, and C. zeyheri, used in African traditional medicine, would
contain ellagitannins with antibacterial (and antimycobacterial) effects (via their urolithins).
3.3. Suggested Antimycobacterial Impact of Ellagic Acid Derivatives in the Species of Combretum Used in This
Study
According to the results of the present study, all the investigated species of Combretum are rich sources
of ellagic acid derivatives. We found that tentatively identified 3′-O-methyl-4-O-(β-d-xylopyranosyl) ellagic
acid was present in large quantities in a butanol extract of C. psidioides stem bark and ellagic acid arabinoside
was present in the stem bark of C. padoides (Tables 4 and 5). Moreover, dimethyl-ellagic acid xyloside
and 3,3′-di-O-methyl-4-O-(n′′-O-galloyl-β-d-xylopyranosyl) ellagic acid were tentatively characterized in
a butanol extract of the stem bark of C. zeyheri (Table 6). To the best of our knowledge, these ellagic acid
derivatives have not previously been found in the mentioned species of Combretum. These ellagic
acid derivatives are suggested to contribute to the good antimycobacterial effects presented in this
study for Combretum psidioides, C. padoides and C. zeyheri since there are a number of reports on good
antimycobacterial effects of ellagic acid derivatives. For example, Kuete et al. [25] reported that
3,4′-di-O-methylellagic-acid-3′-O-β-d-xylopyranoside and 4′-O-galloyl-3,3′-di-O-methylellagic acid
4-O-β-d-xylopyranoside, isolated from the stem bark of Terminalia superba gave promising growth
inhibitory effects against Mycobacterium smegmatis and M. tuberculosis H37Rv as well as a clinical
strain of M. tuberculosis, showing MIC values between 4.88 and 9.76 µg/mL. Moreover, ellagic acid
derivatives, such as 3,3′-di-O-methyl-ellagic acid, has been found to inhibit the synthesis of mycolic
acid, an important cell wall constituent in Mycobacterium spp. [113] and pteleoellagic acid and some
other ellagic acid derivatives revealed good in silico effects on their docking capacity to enzymes
important for the biogenesis of the mycobacterial cell wall [114]. Digalloyl-rhamnopyranosyl ellagic acid
and diellagic lactone isolated from the leaves of Terminalia brownii did not show growth inhibitory effects
against Mycobacterium intracellulare, but showed good growth inhibition against other bacteria such as
Pseudomonas aeruginosa (IC50 8.8. and 8.4 µg/mL, respectively) [115]. In summary, the above-mentioned
findings warrant further studies on the antimycobacterial effects of ellagic acid derivatives in African
species of Combretum.
3.4. Stilbenes in Combretum Psidioides and Their Possible Antimycobacterial Effects
The present study demonstrated that the bibenzyl, combretastatin B-2, and some related
dihydrostilbene derivatives occurred in a methanolic stem bark extract of Combretum psidioides (Figure 4).
Earlier, fourteen phenanthrenes and some bibenzyl derivatives (not including combretastatin B-2) have
been characterized from the stem bark of C. psidioides [63], but these compounds were not investigated
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for their antibacterial effects. Combretastatins and phenanthrenes are known to occur in some other
species of Combretum, the most wellknown source being the stem bark of the South African species
C. caffrum from which a series of antineoplastic combretastatins, among them combretastatin as well
as combretastatins A-1, A-2, A-3, B-1, B-2, B-3, and B-4 have been isolated and characterized [65,116].
Some work has been performed on the antimicrobial effects of stilbenoids and phenanthrenes from
Combretum species: Combretastatin B-5 from the leaves of C. woodii gave good antibacterial effects
against S. aureus with a MIC of 16 µg/mL [67] and phenanthrenes from C. collinum, C. hereroense and C.
apiculatum gave a MIC value of 25 µg/mL against Mycobacterium fortuitum [117]. These results warrant
further studies on the antibacterial and antimycobacterial effects of stilbenoids and phenanthrenes
from the Combretum species used in this study as well as from African Combretum spp. in general.
3.5. Epigallocatechin Gallate
Our results indicated that the green tea polyphenol, epigallocatechin gallate, was present in
a crude methanol extract of the stem bark of C. psidioides (Table 4). This compoud has not been
found before in C. psidioides. Interestingly, epigallocatechin gallate has been shown to affect cell wall
integrity of M. smegmatis mc2155, and is suggested to be a good prophylactic agent for TB [118]. In
addition, it was found that epigallocatechin gallate inhibits the survival of M. tuberculosis within human
macrophages [119]. Moreover, (−)-epigallocatechin gallate has been found to repress the expression of
transcription factor lasB, involved in the quorum sensing system of Pseudomonas aeruginosa [120]. Our
study suggests that more species of Combretum, used for TB in African traditional medicine, should
be explored for their contents of epigallocatechin gallate. Epigallocatechin gallate could be one of
the effective antimycobacterial compounds in the stem bark of C. psidioides.
3.6. Extraction Yield and Its Impact on the Total Antimycobacterial Activity of the Extracts of the Species of
Combretum Used in This Study
When a traditional medicinal plant is evaluated for its usefulness, it is important to measure
the total activity of its extract or isolated fractions/compounds [84]. The total activity is a measure of
the extraction yield of the extracts/fractions divided to the antimicrobial activity of the extracts/fractions
(mg extraction yield/MIC in mg/mL) and indicates the volume in ml to which the active compounds in
1 g of the plant material can be diluted and still inhibits bacterial growth [84].
We found that methanol extraction of the stem bark of C. psidioides results in a high extraction yield
of 19.59% (195.9 mg extracted from 1 g plant material) compared to 10.64% and 15.33%, for C. padoides
and C. zeyheri, respectively (Figure 7). Thus, the methanol stem bark extract of C. psidioides gives
a good total activity of 313.44 mL/g (resulting from dividing the extraction yield to the MIC; 195.9/0.625
= 313.44), and indicates that standardized C. psidioides stem bark extracts could have applications
as antimycobacterial phytomedicines. The extraction yields for C. padoides and C. zeyheri obtained
in the present study are in agreement with the yields mentioned by Masoko et al. [121]. Moreover,
Masoko et al. [121], found that methanol and acetone are suitable solvents for extracting antimicrobials
from Combretum spp.
When the extraction yields of different fractions resulting from solvent partition were compared,
it was observed that the butanol fraction gave the highest yield of 47.52% for Combretum padoides,
and thus resulting in a total antimycobacterial activity of 190.12 mL/g (Table 2, Figure 8). This
means that butanol is an optimal solvent for extracting antimycobacterial compounds, such as ellagic
acid derivatives and ellagitannins from C. padoides. The total extraction yield when using Soxhlet
extraction with methanol was, however, observed to be quite low, 10.61% (Figure 7), resulting in a total
antimycobacterial activity of 85.12 mL/g of this extract (Table 2).
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4. Materials and Methods
4.1. Plant Material and Ethnopharmacological Background Data
The Combretum species were collected from Miombo woodland and riverine forest habitats in
Mbeya and Iringa districts in Tanzania in February–March 1999 [32]. Species identification was
performed by the botanist Mr. Leonard Mwasumbi, the former superintendent of the Herbarium
of the University of Dar-es-Salaam, Tanzania. Voucher specimens are deposited in the Botanical
Museum (H) of the Finnish Museum of Natural History in Helsinki, Finland and at the Herbarium
of the University of Dar-es-Salaam, Tanzania. The Combretum species collected for this study are
presented in Table 1 together with data on their ethnopharmacological uses (with special emphasis on
cough as a symptom of TB), antimicrobial activity, and their phytochemical composition.
4.2. Extraction
4.2.1. Soxhlet Extraction
For each plant sample, 20 g of dried and milled plant material (roots, stem bark, leaves) was
extracted with 500 mL MeOH in a Soxhlet apparatus for 4 h. The extracts were reduced to dryness
under vacuum using a rotary evaporator, the temperature of the water bath not exceeding +40
◦C. For complete drying, the extracts were then further freeze-dried in a lyophilizer for 1–2 days.
The resulting residues were redissolved in MeOH (crude extract) to a final concentration of 50 mg/mL
for antimycobacterial screening.
4.2.2. Solvent Fractionation
Lyophilized crude Soxhlet methanol extracts (1500 mg) of different plant organs of the Combretum
species were dissolved in 50 mL distilled water for 30 min using an ultrasonic bath. The extracts
were centrifuged in order to separate material, which did not dissolve in water (aqueous insoluble
fraction). The aqueous part was used for further fractionation starting with 3 × 25 mL CHCl3:EtOH
(2:1), whereafter 3 × 25 mL n-BuOH was used. The fractionations thus resulted in CHCl3, n-BuOH,
aqueous and aqueous-insoluble fractions. The fractions were evaporated to dryness using a rotary
evaporator and re-dissolved in MeOH to stock solutions of 50 mg/mL for antimycobacterial testing.
4.3. Chromatography and Mass Spectrometry
4.3.1. HPLC-UV/DAD Method I
HPLC analyses for qualitative analysis of extracts of Combretum species were performed as
described in Fyhrquist et al. [122]. The liquid chromatographic system (Waters 600 E) consisted of
a pump and a controller coupled to a 991 PDA detector and a 717 plus automatic sampler under control
of Waters Millennium 2000 software. Samples of 20 µL (20 mg/mL inMeOH) were injected. A reversed
phase Hypersil BDS-C-18 analytical column (250 mm × 4.6 mm ID 5 µm) was used for the separations.
Elution was performed as gradient elution using A) 0.1% formic acid in water and B) 100% acetonitrile.
The gradient started with 85% A and ended with 100% B and the length of the runs were 50–60 min.
The flow rate was 1 mL/min. UV chromatograms were constructed at 254, 280, and 340 nm. UVλ
absorption maxima spectra of the compounds of interest were recorded between 200 and 400 nm using
Millennium 2000 software and compared to reference compounds in the computer library.
4.3.2. HPLC-UV/DAD Method II
A second HPLC-method described in Julkunen-Tiitto et al. [123] and Fyhrquist et al., [122],
developed especially for the detection of polyphenols, was used. The HPLC-system consisted of
a Waters 600 E pump and a controller coupled to a 991 PDA detector and an autosampler under control
of Agilent Chemstation software (Waters Corp., Milford, USA). Samples of 10 µL (2 mg/mL in 50%
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MeOH) were injected. Separations were performed on a reversed phase Hypersil Rp C-18 analytical
column (length: 10 mm; ID: 2 mm; particle size 5 µm). Gradient elution was performed by using
solvent systems as follows: A) Aqueous 1.5% tetrahydrofuran + 0.25% orthophosphoric acid and B)
100% MeOH. The flow rate was 2 mL/min. UV chromatograms were constructed at 220, 270, 280, 320,
and 360 nm. UVλ absorption maxima spectra of compounds, with special emphasis on ellagitannins
and ellagic acid derivatives were compared to the Agilent Chemstation library and to literature [88].
4.3.3. UHPLC/Q-TOF MS Method
Ultra-high pressure liquid chromatography coupled to quadrupole time-of-flight mass
spectrometry was used as a sensitive method to detect molecular masses with four decimal
precision. UHPLC-DAD (Model 1200 Agilent Technologies)-JETSTREAM/QTOFMS (Model 6340
Agilent Technologies) equipped with a 2.1 × 60 mm, 1.7 µm C18 column (Agilent technologies) was
used for the identification of phenolic compounds based on the method described in Taulavuori et
al. [124]. Solvent A was 1.5% tetrahydrofuran and 0.25% acetic acid in HPLC quality water and solvent
B was 100% methanol. Gradient runs were as follows: from 0 to 1.5 min, B 0%, from 1.5 to 3 min, 0
to 15% B, from 3 to 6 min, 10 to 30% B, from 6 to 12 min, 30 to 50% B, from 12 to 20 min, 50 to 100%
B, and from 20 to 22 min, 100 to 0% B. Negative ion mode were used to acquire the mass spectra
depending on the chemical class of the compounds and a mass range from 100 to 2000 m/z was used.
The negative mode was found to be favorable for ellagitannins and ellagic acid derivatives. Pfundstein
et al., [88] was used as the main reference for ellagitannins, ellagic acid derivatives and gallotannins.
Mass measurement error (mass accuracy) was calculated according to Brenton and Godfrey [125]:
Difference between an individual measurement and the true value ∆Mi (in ppm, parts per million) =
(M measured −M calculated) × 106/M calculated, where M measured is the measured mass in QTOF-MS and M
calculated is the exact calculated mass according to the molecular formula of the compound. Negative
mode of qtof was used, and thus the mass of the hydrogen atom (1.0078) was subtracted from all
the calculated masses.
4.3.4. GC-MS Method
The GC-MS analyses were performed on Hewlett-Packard (HP) 5890 GC coupled to an HP
quadrupole mass selective detector operated at ionization voltage of 70 eV (EI-mode). The crude
methanol extract of the stem bark of Combretum psidioides was evaporated and analysed on an NB-54
fused silica capillary column (15 m; 0.20 mm i.d.; Nordion, Finland) using an oven temperature
programming from 70 ◦C to 275 ◦C at 15 ◦C/min. A GC-MS library (The Wiley® Registry of Mass
Spectral Data, John Wiley & Sons Inc., Electronic division, New York, NY, USA) was used for
the elucidation of molecular masses of stilbenoid compounds in the extract.
4.4. Assays for Testing Antimycobacterial Activity
4.4.1. Agar Disk Diffusion
An agar disk diffusion method, explained in detail in Fyhrquist et al. [122], was used. Mycobacterium
smegmatis ATCC 14,468 was grown for five days at +37 ◦C on Löwenstein-Jensen agar slants
(Becton-Dickinson & Company, USA). 200 µL of bacterial culture containing 1.0 × 108 CFU/mL
was inoculated on Petri dishes (∅ = 14 cm, Bibby Sterilin, UK) containing 30 mL Middlebrook 7H10 agar
(Difco) supplemented with OADC supplement (Difco) as a top layer and 30 mL base agar (Antibiotic
agar No 2, Difco) as a bottom layer. Filter paper disks (∅ = 12.7 mm, Schleicher & Schuell) loaded
with 200 µL extracts or fractions (50 and 20 mg/mL, respectively), 200 µL rifampicin (10 mg/mL,
Sigma-Aldrich) and 200 µL MeOH (as negative control) were allowed to dry completely before placing
them equidistantly from each other on the petri dishes. Prior to incubation, the petri dishes were
kept in +4 ◦C for 1 h. The petri dishes were incubated at +37 ◦C for five days. Each extract/fraction
was tested in triplicate and three separate experiments were performed. The diameter of zones of
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inhibition (IZD) were measured with a caliper and the mean of 3 diameters ± SEM was calculated.
Activity index (AI) was measured as the percentage of activity compared to rifampicin, as described by
Fyhrquist et al. [122].
4.4.2. Microplate Dilution Method
A modified microplate assay based on Collins & Franzblau [126] and described in Fyhrquist et
al. [122] was used for measuring minimum inhibitory concentrations of extracts of Combretum spp.
Mycobacterium smegmatis ATCC 14468 was incubated for five days at +37 ◦C on Löwenstein-Jensen agar
slants and transferred into Dubos broth after completed incubation. The absorbance of the samples
was adjusted to 0.1 at 625 nm (approx. 1.0 × 108 CFU/mL) using Dubos broth supplemented with
Dubos broth albumin (Difco) and diluted further to 5.0 × 105 CFU/mL. 100 µL of this inoculum was
added to the wells of the microplates (Nunc, Nunclone, Denmark). 100 µL of two-fold dilutions of
plant extracts (9.76–5000 µg/mL) and of rifampicin (0.9–1000 µg/mL) in Dubos broth or 100 µL Dubos
broth (growth control) were added to the wells of the microplate, so that the final volume in the wells
was 200 µL, thus containing 2.5 × 105 CFU/mL. In order to measure eventual absorption at 620 nm by
the plant extracts or the antibiotic, solvent partition fractions, extracts and rifampicin, alone without
bacteria were used as controls and the absorption produced by these samples was subtracted from
the corresponding samples containing bacterial cells. The solvent control, MeOH at 5% or less, did not
affect the growth of M. smegmatis. The microplates were incubated for four days at +37 ◦C, whereafter
turbidity of the wells at 620 nm was measured using a Victor (Wallac, Finland) spectrophotometer.
The results were calculated as the mean percentage inhibition of the growth control of three replicate
samples ± SEM. The smallest concentration of the extracts and of rifampicin inhibiting 90% or more of
the growth of M. smegmatis and thus resulting in no visible growth was considered as the MIC.
4.5. Calculation of Total Antimycobacterial Activity
The total activity is a measure of the relation of the exraction yield of a plant extract divided to
the MIC of that extract. The total activity indicates the volume into which 1 g of plant extract can
be diluted without losing its antibacterial activity [84]. The total antimycobacterial activity for plant
extracts in this study was calculated as follows:
Total activity (mL/g) = extraction yield of extract A (mg/1000 mg) divided to the MIC of extract A
(in mg/mL).
5. Conclusions
The results of the present study confirm the antimycobacterial potential of butanol, methanol,
and watersoluble extracts of the stem bark of Combretum padoides and C. psidioides and the stem bark
and roots of C. zeyheri. The traditional use of decoctions and macerations of C. zeyheri for the treatment
of cough [81] is justified by these results. The results from this study also suggest that standardized
ethanol and water-based extracts of C. padoides and C. psidioides could be used for the treatment
of tuberculosis, although these species are not mentioned to be used for this purpose in African
traditional medicine.
The growth inhibitory effects of the butanol, methanol and watersoluble extracts of the Combretum
species in this study are suggested to be partly due to ellagitannins and ellagic acid derivatives,
which are abundantly present in these extracts. However, the therapeutic use of ellagitannins for
TB is likely to be limited to their metabolic products, the urolithins, since there is so far only one
report on the occurrence of intact ellagitannins in the plasma of rats after a prolonged intake of ET
rich foods [127].
The ellagic acid derivatives, and especially the glycosides that we have found in the Combretum
species studied, could have an interesting potential as new anti-TB drug scaffolds, since some ellagic
acid derivatives, such as dimethyl ellagic acid xyloside, that was found in the roots of C. zeyheri in
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this investigation, have been found to possess promising antimycobacterial effects, amongst others as
inhibitors of the synthesis of mycolic acid [113].
The results from this study indicate that extracts of Combretum psidioides, C. padoides, and C.
zeyheri should be tested against other mycobacteria, and especially Mycobacterium tuberculosis, since
moderate MIC values against M. smegmatis could imply good MIC values against M. tuberculosis.
The activity guided isolation of active compounds from the butanol extracts, with special emphasis on
ellagic acid derivatives, remains to be performed. Moreover, urolithins resulting from the metabolic
conversion of the ellagitannins punicalagin, corilagin, and saguiin H-4, should be tested for their
antimycobacterial effects.
Lastly, the potential of ellagitannins and ellagic acid derivatives, and other phenolic compounds
from the investigated species of Combretum spp. should be tested as antibiotic adjuvants to enhance
the effects of rifampicin, isoniazid, and other conventional anti-TB drugs.
Supplementary Materials: The following are available online at http://www.mdpi.com/2079-6382/9/8/459/s1,
Figure S1: (A) HPLC-DAD chromatogram of a methanol extract of the stem bark of Combretum psidioides. Rt
7.4, ellagitannin; Rt 7.9, ellagitannin; Rt 8.3, Sanguiin H-4; Rt 10.159, di-galloyl-glucose; Rt 10.9, ellagitannin; Rt
12.4, corilagin; Rt 15.2, punicalagin; Rt 18.0, ellagic acid derivative; Rt 20.2, 3′-O-methyl-4-O-(β-d-xylopyranosyl);
Rt 25.6, ellagitannin; Rt 29.447, ellagitannin; Rt 30.9, ellagitannin; Rt 32.4, ellagitannin; Rt 33.0, ellagitannin; Rt
35.5, ellagitannin; Rt 38.8, hexagalloylglucose; (B) HPLC-DAD chromatogram of a butanol extract of the stem
bark of Combretum psidioides. Rt 7.7, ellagitannin; Rt 8.3, Sanguiin H-4; Rt 10.022, di-galloyl-glucose; Rt
10.776, ellagitannin; Rt 12.244, corilagin; Rt 14.966, punicalagin; Rt 17.565, ellagic acid derivative; Rt 19.846,
3′-O-methyl-4-O-(β-d-xylopyranosyl); Rt 24.922, ellagic acid derivative; Rt 28.605, ellagitannin; Rt 31.560,
ellagitannin; Rt 34.6, ellagitannin; Rt 38.299, hexagalloylglucose. Figure S2: (A) HPLC-DAD chromatograms
a methanol extract of the stem bark of Combretum padoides. Rt 7.4, ellagitannin; Rt 8.45, ellagitannin; Rt
9.765, ellagitannin; Rt 10.898, α-Punicalagin anomer or Punicacortein D; Rt 11.69, ellagitannin; Rt 12.437,
ellagitannin; Rt 15.246, ellagitannin; Rt 20.23, ellagitannin; Rt 20.447, Ellagic acid arabinoside; Rt 21.4,
3′-O-methyl-4-O-(β-d-xylopyranosyl) ellagic acid; Rt 29.435, ellagitannin; Rt 32.427, ellagitannin; Rt 35.560,
ellagitannin; (B) HPLC-DAD chromatograms a butanol extract of the stem bark of Combretum padoides. Rt 7.4,
ellagitannin; Rt 8.45, ellagitannin; Rt 9.768, ellagitannin; Rt 10.903, α-Punicalagin anomer or Punicacortein D;
Rt 11.7, ellagitannin; Rt 12.451, ellagitannin; Rt 15.263, ellagitannin; Rt 20.22, ellagitannin; Rt 20.40, Ellagic acid
arabinoside; Rt 21.4, 3′-O-methyl-4-O-(β-d-xylopyranosyl) ellagic acid; Rt 29.4, ellagitannin; Rt 32.4, ellagitannin;
Rt 35.5, ellagitannin. Figure S3: (A) HPLC-DAD chromatogram of a butanol extract of the stem bark of Combretum
zeyheri. Rt 8.475 min, corilagin derivative; Rt 10.904, ellagitannin; Rt 12.458, ellagitannin; Rt 15.259, gallotannin;
Rt 15.66, punicalagin; Rt 17.630, ellagitannin; Rt 20.554, ellagic acid derivative; Rt 24.066, ellagic acid derivative; Rt
26.641, ellagitannin; Rt 29.9, methyl-ellagic acid xyloside; (B) HPLC-DAD chromatogram of a water-soluble extract
of the stem bark of Combretum zeyheri. Rt 8.475 min, corilagin derivative; Rt 10.904, ellagitannin; Rt 12.458,
ellagitannin; Rt 15.266, gallotannin; Rt 15.671, punicalagin; Rt 17.638, ellagitannin; Rt 20.6, ellagic acid derivative;
Rt 24.051, ellagic acid derivative; Rt 26.661, ellagitannin; Rt 29.275, methyl-ellagic acid xyloside. The water-soluble
extract contains a high concentration of procyanidines, forming the bump shape of the HPLC-chromatogram.
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